Chiu Hsin-Sung, Tsai Meng-Ju Melody, Wang Ting-Ming, Lee Ni-Chung, Tung Yi-Ching
Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan; Department of Pediatrics, National Taiwan University Hospital Yunlin Branch, Douliu, Yunlin, Taiwan.
J Formos Med Assoc. 2025 Jan;124(1):87-90. doi: 10.1016/j.jfma.2024.10.004. Epub 2024 Oct 6.
Hypophosphatemic rickets is a rare metabolic bone disease caused by renal phosphate wasting, leading to impaired bone mineralization. We present a case of a boy with fibroblast growth factor 23 (FGF23)-related hypophosphatemic rickets who did not achieve callus consolidation after six months of conventional therapy with phosphate and active vitamin D following corrective osteotomy. After one month of therapy with an FGF23 antibody (burosumab), the patient demonstrated significant improvement and no longer required a walking aid. Following six months of burosumab therapy, the bone had nearly fully healed. This report is the first to address the short-term use of burosumab therapy to promote bone healing after orthopedic surgery. Our findings further emphasize the clinical advantages and short-term applications of burosumab in FGF23-related hypophosphatemic diseases, especially for patients undergoing orthopedic surgery.
低磷性佝偻病是一种罕见的代谢性骨病，由肾性磷酸盐流失引起，导致骨矿化受损。我们报告一例与成纤维细胞生长因子23（FGF23）相关的低磷性佝偻病男孩病例，该男孩在进行截骨矫正术后，接受磷酸盐和活性维生素D常规治疗六个月后，骨痂仍未愈合。在用FGF23抗体（布罗索尤单抗）治疗一个月后，患者病情显著改善，不再需要助行器。经过六个月的布罗索尤单抗治疗后，骨骼几乎完全愈合。本报告首次探讨了布罗索尤单抗治疗在促进骨科手术后骨愈合方面的短期应用。我们的研究结果进一步强调了布罗索尤单抗在FGF23相关低磷性疾病中的临床优势和短期应用，特别是对于接受骨科手术的患者。
